NCT04097301 · MORE INFO

Limitations, agreements, and source contact

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma · Source last updated 2022-01-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: The Company will keep the information related to the trial in the strictest confidence and won't disclose such confidential information to third parties without the written consent of the Sponsor. It warrants that the obligation of confidentiality will be extended to the PI, his collaborators and to any other person who may become aware of confidential data. These obligations will remain in effect until the information is released into the public domain by the by the Sponsor.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: The early termination of this study is due to the analysis of its feasibility, based on the low patient recruitment rate (due to the lower-than-expected proportion of myeloma and leukemia expressing the CD44v6). A further decrease in the recruitment occurred with the diffusion of the COVID-19 emergency and the availability of new drugs for the treatment of myeloma and leukemia. These reasons make impossible to foresee the conclusion of the study in a clinically relevant time frame.

point Of Contact

Complete source fields

certain Agreement

other Details: The Company will keep the information related to the trial in the strictest confidence and won't disclose such confidential information to third parties without the written consent of the Sponsor. It warrants that the obligation of confidentiality will be extended to the PI, his collaborators and to any other person who may become aware of confidential data. These obligations will remain in effect until the information is released into the public domain by the by the Sponsor.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: The early termination of this study is due to the analysis of its feasibility, based on the low patient recruitment rate (due to the lower-than-expected proportion of myeloma and leukemia expressing the CD44v6). A further decrease in the recruitment occurred with the diffusion of the COVID-19 emergency and the availability of new drugs for the treatment of myeloma and leukemia. These reasons make impossible to foresee the conclusion of the study in a clinically relevant time frame.

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice